FDMT Jan 2025 35.000 call
| Previous close | 2.3500 |
| Open | N/A |
| Bid | 1.0500 |
| Ask | 3.4000 |
| Strike | 35.00 |
| Expiry date | 2025-01-17 |
| Day's range | 2.3500 - 2.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
GlobeNewswire4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
4D-175 comprises the proprietary low-dose intravitreal R100 AAV vector and a codon-optimized transgene encoding a highly functional shortened form of human complement factor H (sCFH)Complement factor H (CFH) variants with reduced function are a well-validated genetic risk factor for geographic atrophy (GA), with approximately 75% of age-related macular degeneration (AMD) patients carrying a high-risk variant of CFHOver 150 patients have been treated with the R100 vector, including those with wet
- GlobeNewswire
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be presented (N=30 at 3E10 vg/eye)Clinical data will be presented by Raj K. Maturi, M.D., a Principal Investigator in the PRISM study, at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting on July 17, 2024 at 8:49 a.m. CESTCompany to provide a high-level safety update on 4D-150 treated patients from PRISM and SPECTRA studies (N=139) Company to host w
- GlobeNewswire
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than in the standard bimonthly aflibercept control group at all six timepoints through Week 24Single intravitreal 3E10 vg/eye dose resulted in sustained reduction and stabilization of mean central subfield thickness (CST) compared to aflibercept at all timepoints In the 3E10 vg/eye injection-free sub
